TG Therapeutics, Inc. $TGTX Shares Acquired by BNP Paribas Financial Markets

BNP Paribas Financial Markets grew its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) by 856.6% during the 4th quarter, Holdings Channel reports. The firm owned 683,653 shares of the biopharmaceutical company’s stock after buying an additional 612,189 shares during the period. BNP Paribas Financial Markets’ holdings in TG Therapeutics were worth $20,380,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of TGTX. Royal Bank of Canada lifted its stake in shares of TG Therapeutics by 16.4% during the first quarter. Royal Bank of Canada now owns 75,692 shares of the biopharmaceutical company’s stock valued at $2,985,000 after buying an additional 10,660 shares during the period. NewEdge Advisors LLC lifted its stake in shares of TG Therapeutics by 9.6% during the first quarter. NewEdge Advisors LLC now owns 7,593 shares of the biopharmaceutical company’s stock valued at $299,000 after buying an additional 665 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of TG Therapeutics by 21.9% during the first quarter. Goldman Sachs Group Inc. now owns 1,919,416 shares of the biopharmaceutical company’s stock valued at $75,683,000 after buying an additional 345,059 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of TG Therapeutics by 5.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 287,059 shares of the biopharmaceutical company’s stock valued at $11,319,000 after buying an additional 14,689 shares during the period. Finally, EverSource Wealth Advisors LLC lifted its stake in shares of TG Therapeutics by 86.3% during the second quarter. EverSource Wealth Advisors LLC now owns 1,237 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 573 shares during the period. Hedge funds and other institutional investors own 58.58% of the company’s stock.

Analysts Set New Price Targets

TGTX has been the topic of several recent analyst reports. Wall Street Zen downgraded shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Zacks Research raised shares of TG Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, June 1st. HC Wainwright reaffirmed a “buy” rating and set a $70.00 price target on shares of TG Therapeutics in a research note on Wednesday, May 27th. Finally, Weiss Ratings raised shares of TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, TG Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $52.50.

TG Therapeutics Stock Performance

Shares of TGTX stock opened at $40.16 on Friday. The company’s fifty day simple moving average is $37.05 and its 200-day simple moving average is $32.59. TG Therapeutics, Inc. has a 52 week low of $25.28 and a 52 week high of $44.65. The company has a current ratio of 5.81, a quick ratio of 5.12 and a debt-to-equity ratio of 1.28. The company has a market cap of $6.15 billion, a PE ratio of 14.04 and a beta of 1.68.

TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.11). The business had revenue of $204.92 million during the quarter, compared to analysts’ expectations of $200.33 million. TG Therapeutics had a net margin of 65.95% and a return on equity of 88.73%. The business’s revenue was up 69.5% on a year-over-year basis. During the same period in the prior year, the business posted $0.03 EPS. As a group, equities research analysts anticipate that TG Therapeutics, Inc. will post 1.51 EPS for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.